RT @BenedettaConte5: Great presentation of @FrancescoSche20 on network meta-analysis recently published in @TheLancetOncol on the efficacy…
Excelente información para leer #breastcancer
RT @BenedettaConte5: Great presentation of @FrancescoSche20 on network meta-analysis recently published in @TheLancetOncol on the efficacy…
Great presentation of @FrancescoSche20 on network meta-analysis recently published in @TheLancetOncol on the efficacy of endocrine therapy vs chemotherapy in luminal #metastatic #breastcancer. Check the full paper here: https://t.co/T1vwjXPwpp #AIOM2020
RT @academiamir: En mujeres con #cáncerdeMama metastásico con receptor hormonal positivo y HER2 negativo los inhibidores de CDK4/6 más las…
RT @academiamir: En mujeres con #cáncerdeMama metastásico con receptor hormonal positivo y HER2 negativo los inhibidores de CDK4/6 más las…
RT @academiamir: En mujeres con #cáncerdeMama metastásico con receptor hormonal positivo y HER2 negativo los inhibidores de CDK4/6 más las…
En mujeres con #cáncerdeMama metastásico con receptor hormonal positivo y HER2 negativo los inhibidores de CDK4/6 más las terapias hormonales son mejores que las terapias hormonales estándar en cuanto a supervivencia libre de progresión. https://t.co/gMKqR
New2Trip: Endocrine treatment versus chemotherapy in postmenopausal women w/ hormone receptor-positive, HER2-negative, metastatic breast cancer: systematic review & network meta-analysis https://t.co/qVnbAaoTfr
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis - The Lancet Oncology https://t.co/CfSNvSIC6m
RT @Yoh_tw: 2686本という数に感服する https://t.co/zDyjlAsmWn
RT @TheLancetOncol: Now in the Oct issue: systematic review and network meta-analysis of #endocrine treatment vs #chemotherapy in postmenop…
RT @m0370: 閉経後HR陽性HER2陰性進行乳癌の2689本の文献と140の試験の5万人の患者からシステマチック統合解析。2000年〜と古いデータも含まれてるけど、結果はCDK4/6i+ETがET単剤にPFS優越だけでなく、PTX+Bev以外のほぼ全ての化学療法もCDK…
RT @nelsonusnayo: Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic…
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis https://t.co/d9QySWurnc
2686本という数に感服する
RT @TheLancetOncol: Now in the Oct issue: systematic review and network meta-analysis of #endocrine treatment vs #chemotherapy in postmenop…
RT @TheLancetOncol: Now in the Oct issue: systematic review and network meta-analysis of #endocrine treatment vs #chemotherapy in postmenop…
RT @m0370: 閉経後HR陽性HER2陰性進行乳癌の2689本の文献と140の試験の5万人の患者からシステマチック統合解析。2000年〜と古いデータも含まれてるけど、結果はCDK4/6i+ETがET単剤にPFS優越だけでなく、PTX+Bev以外のほぼ全ての化学療法もCDK…
RT @TheLancetOncol: Now in the Oct issue: systematic review and network meta-analysis of #endocrine treatment vs #chemotherapy in postmenop…
RT @TheLancetOncol: Now in the Oct issue: systematic review and network meta-analysis of #endocrine treatment vs #chemotherapy in postmenop…
RT @m0370: 閉経後HR陽性HER2陰性進行乳癌の2689本の文献と140の試験の5万人の患者からシステマチック統合解析。2000年〜と古いデータも含まれてるけど、結果はCDK4/6i+ETがET単剤にPFS優越だけでなく、PTX+Bev以外のほぼ全ての化学療法もCDK…
RT @TheLancetOncol: Now in the Oct issue: systematic review and network meta-analysis of #endocrine treatment vs #chemotherapy in postmenop…
RT @TheLancetOncol: Now in the Oct issue: systematic review and network meta-analysis of #endocrine treatment vs #chemotherapy in postmenop…
RT @m0370: 閉経後HR陽性HER2陰性進行乳癌の2689本の文献と140の試験の5万人の患者からシステマチック統合解析。2000年〜と古いデータも含まれてるけど、結果はCDK4/6i+ETがET単剤にPFS優越だけでなく、PTX+Bev以外のほぼ全ての化学療法もCDK…
閉経後HR陽性HER2陰性進行乳癌の2689本の文献と140の試験の5万人の患者からシステマチック統合解析。2000年〜と古いデータも含まれてるけど、結果はCDK4/6i+ETがET単剤にPFS優越だけでなく、PTX+Bev以外のほぼ全ての化学療法もCDK4/6i+ETに勝てず。 /Lancet Oncol https://t.co/MJD2cEXJgT
RT @TheLancetOncol: Now in the Oct issue: systematic review and network meta-analysis of #endocrine treatment vs #chemotherapy in postmenop…
RT @TheLancetOncol: Now in the Oct issue: systematic review and network meta-analysis of #endocrine treatment vs #chemotherapy in postmenop…
Now in the Oct issue: systematic review and network meta-analysis of #endocrine treatment vs #chemotherapy in postmenopausal women with hormone receptor+ HER2– #metastatic #breastcancer https://t.co/RNGM3Pbp3a
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
RT @Dr_Anna_Ryan: A 50,000 patient meta analysis confirming that first line endocrine + CDK46i gives best outcome in ER+ve metastatic #brea…
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
RT @Dr_Anna_Ryan: A 50,000 patient meta analysis confirming that first line endocrine + CDK46i gives best outcome in ER+ve metastatic #brea…
RT @Dr_Anna_Ryan: A 50,000 patient meta analysis confirming that first line endocrine + CDK46i gives best outcome in ER+ve metastatic #brea…
RT @Dr_Anna_Ryan: A 50,000 patient meta analysis confirming that first line endocrine + CDK46i gives best outcome in ER+ve metastatic #brea…
A 50,000 patient meta analysis confirming that first line endocrine + CDK46i gives best outcome in ER+ve metastatic #breastcancer Always treat the biology, even in very widespread disease @delmastro_lucia #OncoAlert
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
Endocrine treatment versus chemotherapy in postmenopausal women with h... https://t.co/kn9Slefi7N
Endocrine treatment versus chemotherapy in postmenopausal women with h... https://t.co/kgfkYn5wm9
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
RT @gedefo_sefh: Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic…
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
RT @gedefo_sefh: Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic…
RT @gedefo_sefh: Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic…
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis - ScienceDirect https://t.co/lxM3DvOvy0
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
RT @delmastro_lucia: Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chem…
Published in @TheLancetOncol our network metanalysis showing the importance of preferring #EndocrineTherapy over #chemotherapy in patients with #HormoneReceptor-positive advanced #BreastCancer not in visceral crisis #OncoAlert @OncoAlert #bcsm @prat_aleix
RT @zeromtmu: Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic bre…
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis - The Lancet Oncology https://t.co/1TyaQHOk2l
乳癌薬物療法で、1st,2nd ラインの治療において、ホルモン療法にCDK4/6阻害薬の併用は標準的ホルモン療法に比べてPFSを有意に改善した。 標的療法の併用有無に関わらず、化学療法は、CDK4/6阻害薬とホルモン療法の併用よりもPFSは有意に改善しなかった。 https://t.co/HHzy218tIf PMID:31494037
RT @MamMa_mimumemo: ER陽性乳がんの再発治療のネットワーク解析。ホルモン療法も化学療法も含めて比較。 細かな話は色々あれど、結論は、PFSでみれば、CDK4/6阻害薬最強説。 化学療法でアロマターゼ阻害薬を上回れるレジメンは限られていて、ER陽性乳がんへのホ…
RT @MamMa_mimumemo: ER陽性乳がんの再発治療のネットワーク解析。ホルモン療法も化学療法も含めて比較。 細かな話は色々あれど、結論は、PFSでみれば、CDK4/6阻害薬最強説。 化学療法でアロマターゼ阻害薬を上回れるレジメンは限られていて、ER陽性乳がんへのホ…
RT @MamMa_mimumemo: ER陽性乳がんの再発治療のネットワーク解析。ホルモン療法も化学療法も含めて比較。 細かな話は色々あれど、結論は、PFSでみれば、CDK4/6阻害薬最強説。 化学療法でアロマターゼ阻害薬を上回れるレジメンは限られていて、ER陽性乳がんへのホ…
RT @MamMa_mimumemo: ER陽性乳がんの再発治療のネットワーク解析。ホルモン療法も化学療法も含めて比較。 細かな話は色々あれど、結論は、PFSでみれば、CDK4/6阻害薬最強説。 化学療法でアロマターゼ阻害薬を上回れるレジメンは限られていて、ER陽性乳がんへのホ…
RT @MamMa_mimumemo: ER陽性乳がんの再発治療のネットワーク解析。ホルモン療法も化学療法も含めて比較。 細かな話は色々あれど、結論は、PFSでみれば、CDK4/6阻害薬最強説。 化学療法でアロマターゼ阻害薬を上回れるレジメンは限られていて、ER陽性乳がんへのホ…
RT @MamMa_mimumemo: ER陽性乳がんの再発治療のネットワーク解析。ホルモン療法も化学療法も含めて比較。 細かな話は色々あれど、結論は、PFSでみれば、CDK4/6阻害薬最強説。 化学療法でアロマターゼ阻害薬を上回れるレジメンは限られていて、ER陽性乳がんへのホ…
RT @MamMa_mimumemo: ER陽性乳がんの再発治療のネットワーク解析。ホルモン療法も化学療法も含めて比較。 細かな話は色々あれど、結論は、PFSでみれば、CDK4/6阻害薬最強説。 化学療法でアロマターゼ阻害薬を上回れるレジメンは限られていて、ER陽性乳がんへのホ…
RT @MamMa_mimumemo: ER陽性乳がんの再発治療のネットワーク解析。ホルモン療法も化学療法も含めて比較。 細かな話は色々あれど、結論は、PFSでみれば、CDK4/6阻害薬最強説。 化学療法でアロマターゼ阻害薬を上回れるレジメンは限られていて、ER陽性乳がんへのホ…
RT @MamMa_mimumemo: ER陽性乳がんの再発治療のネットワーク解析。ホルモン療法も化学療法も含めて比較。 細かな話は色々あれど、結論は、PFSでみれば、CDK4/6阻害薬最強説。 化学療法でアロマターゼ阻害薬を上回れるレジメンは限られていて、ER陽性乳がんへのホ…
RT @MamMa_mimumemo: ER陽性乳がんの再発治療のネットワーク解析。ホルモン療法も化学療法も含めて比較。 細かな話は色々あれど、結論は、PFSでみれば、CDK4/6阻害薬最強説。 化学療法でアロマターゼ阻害薬を上回れるレジメンは限られていて、ER陽性乳がんへのホ…
RT @MamMa_mimumemo: ER陽性乳がんの再発治療のネットワーク解析。ホルモン療法も化学療法も含めて比較。 細かな話は色々あれど、結論は、PFSでみれば、CDK4/6阻害薬最強説。 化学療法でアロマターゼ阻害薬を上回れるレジメンは限られていて、ER陽性乳がんへのホ…
RT @MamMa_mimumemo: ER陽性乳がんの再発治療のネットワーク解析。ホルモン療法も化学療法も含めて比較。 細かな話は色々あれど、結論は、PFSでみれば、CDK4/6阻害薬最強説。 化学療法でアロマターゼ阻害薬を上回れるレジメンは限られていて、ER陽性乳がんへのホ…
ER陽性乳がんの再発治療のネットワーク解析。ホルモン療法も化学療法も含めて比較。 細かな話は色々あれど、結論は、PFSでみれば、CDK4/6阻害薬最強説。 化学療法でアロマターゼ阻害薬を上回れるレジメンは限られていて、ER陽性乳がんへのホルモン療法の偉大さを再認識。 https://t.co/hyldmAGUnp
RT @SIS_Breast: In the first-line or second-line setting, CDK4/6 inhibitors plus hormone therapies are better than standard hormone therapi…
In the first-line or second-line setting, CDK4/6 inhibitors plus hormone therapies are better than standard hormone therapies in terms of progression-free survival. https://t.co/TfZaHaUcts
RT @tkdmHawkeye: ER陽性転移性乳がんに対するCDK4/6阻害剤+内分泌療法の効果は従来の抗癌剤をしのぐというメタアナリシス https://t.co/LiHTpCsSdm
RT @tkdmHawkeye: ER陽性転移性乳がんに対するCDK4/6阻害剤+内分泌療法の効果は従来の抗癌剤をしのぐというメタアナリシス https://t.co/LiHTpCsSdm
RT @tkdmHawkeye: ER陽性転移性乳がんに対するCDK4/6阻害剤+内分泌療法の効果は従来の抗癌剤をしのぐというメタアナリシス https://t.co/LiHTpCsSdm
RT @tkdmHawkeye: ER陽性転移性乳がんに対するCDK4/6阻害剤+内分泌療法の効果は従来の抗癌剤をしのぐというメタアナリシス https://t.co/LiHTpCsSdm
ER陽性転移性乳がんに対するCDK4/6阻害剤+内分泌療法の効果は従来の抗癌剤をしのぐというメタアナリシス https://t.co/LiHTpCsSdm
【システマチックレビュー・ネットワークメタアナリシス】ホルモン受容体陽性、HER2陰性の転移性乳癌の閉経後女性での内分泌療法対化学療法(一次治療、二次治療において、CDK4/6阻害薬+ホルモン療法は、無増悪生存期間の面から標準的なホルモン療法よりも優れていた。) https://t.co/BMIEAci3bs
RT @NatRevClinOncol: In an meta-analysis in HER2-/HR+ mBC, CDK4/6i + hormone therapy is better than standard hormone therapies in terms of…
RT @NatRevClinOncol: In an meta-analysis in HER2-/HR+ mBC, CDK4/6i + hormone therapy is better than standard hormone therapies in terms of…
RT @NatRevClinOncol: In an meta-analysis in HER2-/HR+ mBC, CDK4/6i + hormone therapy is better than standard hormone therapies in terms of…
RT @NatRevClinOncol: In an meta-analysis in HER2-/HR+ mBC, CDK4/6i + hormone therapy is better than standard hormone therapies in terms of…
RT @NatRevClinOncol: In an meta-analysis in HER2-/HR+ mBC, CDK4/6i + hormone therapy is better than standard hormone therapies in terms of…
RT @NatRevClinOncol: In an meta-analysis in HER2-/HR+ mBC, CDK4/6i + hormone therapy is better than standard hormone therapies in terms of…
RT @NatRevClinOncol: In an meta-analysis in HER2-/HR+ mBC, CDK4/6i + hormone therapy is better than standard hormone therapies in terms of…
RT @NatRevClinOncol: In an meta-analysis in HER2-/HR+ mBC, CDK4/6i + hormone therapy is better than standard hormone therapies in terms of…
RT @NatRevClinOncol: In an meta-analysis in HER2-/HR+ mBC, CDK4/6i + hormone therapy is better than standard hormone therapies in terms of…
RT @NatRevClinOncol: In an meta-analysis in HER2-/HR+ mBC, CDK4/6i + hormone therapy is better than standard hormone therapies in terms of…
In an meta-analysis in HER2-/HR+ mBC, CDK4/6i + hormone therapy is better than standard hormone therapies in terms of PFS; no chemotherapy regimen with or without targeted therapy provides better PFS than CDK4/6i + hormone therapy: https://t.co/4ZWLvdQLMH
RT @MCristofanill: Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastati…
RT @PubMedTrending: Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastat…
RT @researchphilia: 🔬 Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metast…
RT @researchphilia: 🔬 Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metast…
🔬 Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. 📝 Lancet Oncol. 👨🏻🔬 Giuliano M, et al. 🌎 https://t.co/3mdsIeIj00 #sci
RT @MCristofanill: Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastati…
RT @MCristofanill: Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastati…